Drug-induced movement disorders

Shyamal Mehta, Kapil D. Sethi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Movement disorders attributable to prescribed medications and drugs of abuse are commonly encountered in the clinic. This chapter will review the wide variety of movement disorders due to dopamine-receptor blocking agents (DBAs), other medications, and the drugs of abuse. Movement disorders due to DBAs Antipsychotic agents, also termed neuroleptics or dopamine-receptor blocking agents (DBAs), are extensively utilized in the management of psychiatric disorders such as schizophrenia and bipolar disorders, and DBAs are employed in the treatment of neurological diseases such as Tourette’s syndrome, Huntington’s disease, psychosis in Parkinson’s disease, and dementias such as dementia with Lewy bodies. In addition, metoclopramide (MCP) is widely used to treat gastrointestinal motility disorders. The introduction of chlorpromazine in the early 1950s was nothing short of a miracle in the treatment of psychosis, but it was soon realized that there were significant neurological side effects associated with this class of drugs. Extrapyramidal side effects (EPS) was an umbrella term used to describe these side effects. Initially, it was thought that the induction of EPS was integral to the clinical antipsychotic efficacy of chlorpromazine and a dopamine depleter reserpine. More recently with the advent of clozapine, this tight linkage between EPS and antipsychotic efficacy has been shown to be fallacious. The evidence implicates the degree of D2 receptor antagonism and the speed of dissociation in the development of these EPS (DBAs with less D2 affinity and more rapid dissociation are less likely to produce EPS). In addition, the blockage of other neurotransmitter receptors such as 5-hydroxytryptamine (5-HT2) receptors may be important, allowing the development of drugs that are less likely to cause movement disorders.

Original languageEnglish (US)
Title of host publicationMovement Disorders in Neurologic and Systemic Disease
PublisherCambridge University Press
Pages203-219
Number of pages17
ISBN (Electronic)9781139175845
ISBN (Print)9781107024618
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Dopamine Receptors
Movement Disorders
Antipsychotic Agents
Pharmaceutical Preparations
Chlorpromazine
Street Drugs
Psychotic Disorders
Dissociative Disorders
Lewy Body Disease
Tourette Syndrome
Metoclopramide
Neurotransmitter Receptor
Gastrointestinal Motility
Clozapine
Reserpine
Huntington Disease
Bipolar Disorder
Parkinson Disease
Psychiatry
Dementia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mehta, S., & Sethi, K. D. (2012). Drug-induced movement disorders. In Movement Disorders in Neurologic and Systemic Disease (pp. 203-219). Cambridge University Press. https://doi.org/10.1017/CBO9781139175845.015

Drug-induced movement disorders. / Mehta, Shyamal; Sethi, Kapil D.

Movement Disorders in Neurologic and Systemic Disease. Cambridge University Press, 2012. p. 203-219.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mehta, S & Sethi, KD 2012, Drug-induced movement disorders. in Movement Disorders in Neurologic and Systemic Disease. Cambridge University Press, pp. 203-219. https://doi.org/10.1017/CBO9781139175845.015
Mehta S, Sethi KD. Drug-induced movement disorders. In Movement Disorders in Neurologic and Systemic Disease. Cambridge University Press. 2012. p. 203-219 https://doi.org/10.1017/CBO9781139175845.015
Mehta, Shyamal ; Sethi, Kapil D. / Drug-induced movement disorders. Movement Disorders in Neurologic and Systemic Disease. Cambridge University Press, 2012. pp. 203-219
@inbook{1e08016d755e49d9855c3ae144fc7b0b,
title = "Drug-induced movement disorders",
abstract = "Movement disorders attributable to prescribed medications and drugs of abuse are commonly encountered in the clinic. This chapter will review the wide variety of movement disorders due to dopamine-receptor blocking agents (DBAs), other medications, and the drugs of abuse. Movement disorders due to DBAs Antipsychotic agents, also termed neuroleptics or dopamine-receptor blocking agents (DBAs), are extensively utilized in the management of psychiatric disorders such as schizophrenia and bipolar disorders, and DBAs are employed in the treatment of neurological diseases such as Tourette’s syndrome, Huntington’s disease, psychosis in Parkinson’s disease, and dementias such as dementia with Lewy bodies. In addition, metoclopramide (MCP) is widely used to treat gastrointestinal motility disorders. The introduction of chlorpromazine in the early 1950s was nothing short of a miracle in the treatment of psychosis, but it was soon realized that there were significant neurological side effects associated with this class of drugs. Extrapyramidal side effects (EPS) was an umbrella term used to describe these side effects. Initially, it was thought that the induction of EPS was integral to the clinical antipsychotic efficacy of chlorpromazine and a dopamine depleter reserpine. More recently with the advent of clozapine, this tight linkage between EPS and antipsychotic efficacy has been shown to be fallacious. The evidence implicates the degree of D2 receptor antagonism and the speed of dissociation in the development of these EPS (DBAs with less D2 affinity and more rapid dissociation are less likely to produce EPS). In addition, the blockage of other neurotransmitter receptors such as 5-hydroxytryptamine (5-HT2) receptors may be important, allowing the development of drugs that are less likely to cause movement disorders.",
author = "Shyamal Mehta and Sethi, {Kapil D.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1017/CBO9781139175845.015",
language = "English (US)",
isbn = "9781107024618",
pages = "203--219",
booktitle = "Movement Disorders in Neurologic and Systemic Disease",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Drug-induced movement disorders

AU - Mehta, Shyamal

AU - Sethi, Kapil D.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Movement disorders attributable to prescribed medications and drugs of abuse are commonly encountered in the clinic. This chapter will review the wide variety of movement disorders due to dopamine-receptor blocking agents (DBAs), other medications, and the drugs of abuse. Movement disorders due to DBAs Antipsychotic agents, also termed neuroleptics or dopamine-receptor blocking agents (DBAs), are extensively utilized in the management of psychiatric disorders such as schizophrenia and bipolar disorders, and DBAs are employed in the treatment of neurological diseases such as Tourette’s syndrome, Huntington’s disease, psychosis in Parkinson’s disease, and dementias such as dementia with Lewy bodies. In addition, metoclopramide (MCP) is widely used to treat gastrointestinal motility disorders. The introduction of chlorpromazine in the early 1950s was nothing short of a miracle in the treatment of psychosis, but it was soon realized that there were significant neurological side effects associated with this class of drugs. Extrapyramidal side effects (EPS) was an umbrella term used to describe these side effects. Initially, it was thought that the induction of EPS was integral to the clinical antipsychotic efficacy of chlorpromazine and a dopamine depleter reserpine. More recently with the advent of clozapine, this tight linkage between EPS and antipsychotic efficacy has been shown to be fallacious. The evidence implicates the degree of D2 receptor antagonism and the speed of dissociation in the development of these EPS (DBAs with less D2 affinity and more rapid dissociation are less likely to produce EPS). In addition, the blockage of other neurotransmitter receptors such as 5-hydroxytryptamine (5-HT2) receptors may be important, allowing the development of drugs that are less likely to cause movement disorders.

AB - Movement disorders attributable to prescribed medications and drugs of abuse are commonly encountered in the clinic. This chapter will review the wide variety of movement disorders due to dopamine-receptor blocking agents (DBAs), other medications, and the drugs of abuse. Movement disorders due to DBAs Antipsychotic agents, also termed neuroleptics or dopamine-receptor blocking agents (DBAs), are extensively utilized in the management of psychiatric disorders such as schizophrenia and bipolar disorders, and DBAs are employed in the treatment of neurological diseases such as Tourette’s syndrome, Huntington’s disease, psychosis in Parkinson’s disease, and dementias such as dementia with Lewy bodies. In addition, metoclopramide (MCP) is widely used to treat gastrointestinal motility disorders. The introduction of chlorpromazine in the early 1950s was nothing short of a miracle in the treatment of psychosis, but it was soon realized that there were significant neurological side effects associated with this class of drugs. Extrapyramidal side effects (EPS) was an umbrella term used to describe these side effects. Initially, it was thought that the induction of EPS was integral to the clinical antipsychotic efficacy of chlorpromazine and a dopamine depleter reserpine. More recently with the advent of clozapine, this tight linkage between EPS and antipsychotic efficacy has been shown to be fallacious. The evidence implicates the degree of D2 receptor antagonism and the speed of dissociation in the development of these EPS (DBAs with less D2 affinity and more rapid dissociation are less likely to produce EPS). In addition, the blockage of other neurotransmitter receptors such as 5-hydroxytryptamine (5-HT2) receptors may be important, allowing the development of drugs that are less likely to cause movement disorders.

UR - http://www.scopus.com/inward/record.url?scp=84928080202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928080202&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139175845.015

DO - 10.1017/CBO9781139175845.015

M3 - Chapter

AN - SCOPUS:84928080202

SN - 9781107024618

SP - 203

EP - 219

BT - Movement Disorders in Neurologic and Systemic Disease

PB - Cambridge University Press

ER -